Inhibikase Therapeutics Inc (NAS:IKT)
$ 2.73 0.37 (15.68%) Market Cap: 183.44 Mil Enterprise Value: 180.34 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 38/100

Inhibikase Therapeutics Inc at B Riley Neuro & Ophthalmology Conference (Virtual) Transcript

Apr 28, 2022 / 06:30PM GMT
Release Date Price: $6.03 (-6.94%)
William Wood
B. Riley Financial, Inc. - Analyst

Welcome back to our next fireside chat. We are delighted to introduce Inhibikase Therapeutics. We have with us today Dr. Milton Werner, President and CEO of Inhibikase.

Dr. Werner, thanks for being with us here today. We really appreciate you taking the time. Perhaps it would be helpful for the audience if you could start by covering or providing a brief overview of the company, including the key strategic objectives, your lead candidate, and then the initial indications you're targeting.

Milton Werner
Inhibikase Therapeutics, Inc. - President & CEO

Sure. Thanks a lot, William, and thanks to B. Riley and for everyone for attending this fireside chat. Inhibikase is an old-fashioned entrepreneurial start-up founded initially in 2008, then went Delaware C in 2010. It was funded by revenue all the way up to our IPO for the most part, not your typical story.

So we built in a lot of business discipline behind our portfolio of small molecule enzyme inhibitors that inhibit what is known are the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot